Johnson & Johnson reported third-quarter profits exceeding expectations, driven by strong Tremfya sales, though geopolitical tensions in the Middle East hindered medical device revenue growth. The com
Johnson & Johnson beat Q2 sales and profit estimates, driven by strong growth in key drugs like Tremfya and Darzalex. It raised its full-year forecast despite challenges in its medical technology unit
A Los Angeles jury ruled in favor of Johnson & Johnson in a lawsuit claiming its talc products caused ovarian cancer. J&J faces over 67,000 similar suits but halted U.S. talc-based baby powder sales i
Johnson & Johnson beat first-quarter earnings estimates with $24.1 billion revenue, raising its full-year forecast despite a 60% drop in Stelara sales due to biosimilar competition. Growth in cancer a
ChemBrief